Influence of Intestinal Barrier on Alleviating an Increase in Blood Pressure by Sodium Alginate Intake in 2-Kidney, 1-Clip Renovascular Hypertensive Rats

Mar Drugs. 2023 May 26;21(6):324. doi: 10.3390/md21060324.

Abstract

Sodium alginate (SALG) is a substance derived from brown seaweed that has been shown to reduce blood pressure (BP). However, its effects on renovascular hypertension caused by 2-kidney, 1-clip (2K1C) are not yet clear. Previous research suggests that hypertensive rats have increased intestinal permeability, and that SALG improves the gut barrier in inflammatory bowel disease mouse models. Therefore, the goal of this study was to determine whether the antihypertensive effects of SALG involve the intestinal barrier in 2K1C rats. Rats were fed either a 1.0% SALG diet or a control diet for six weeks after being subjected to 2K1C surgery or a sham operation. The systolic BP was measured weekly, and the mean arterial BP was measured at the end of the study. Intestinal samples were taken for analysis, and plasma lipopolysaccharide (LPS) levels were measured. The results showed that BP in 2K1C rats was significantly higher than in SHAM rats when fed CTL, but not when fed SALG. The gut barrier in 2K1C rats was improved by SALG intake. Plasma LPS levels also differed depending on the animal model and diet. In conclusion, dietary SALG may alleviate 2K1C renovascular hypertension by altering the gut barrier.

Keywords: gut barrier; prevention of hypertension; renovascular hypertension; sodium alginate.

MeSH terms

  • Alginates / pharmacology
  • Animals
  • Blood Pressure
  • Disease Models, Animal
  • Hypertension, Renovascular* / drug therapy
  • Hypertension, Renovascular* / etiology
  • Kidney
  • Lipopolysaccharides / pharmacology
  • Mice
  • Rats
  • Surgical Instruments / adverse effects

Substances

  • Alginates
  • Lipopolysaccharides